Effects of loratadine, a histamine H
bone
histamine H1 receptor antagonists
loratadine
rats
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
05
2019
accepted:
26
07
2019
entrez:
3
10
2019
pubmed:
3
10
2019
medline:
9
4
2020
Statut:
epublish
Résumé
Histamine H The aim of the present study was to investigate the effects of loratadine on the skeletal system of young rats. Loratadine (0.5, 5, and 50 mg/kg p.o. daily) was administered for 4 weeks to male Wistar rats, 6-week-old at the start of the experiment. Bone mass, mass of bone mineral, calcium, and phosphorus content in the bone mineral of the tibia, femur, and L-4 vertebra, histomorphometric parameters of the femur, mechanical properties of the proximal tibial metaphysis, femoral diaphysis and femoral neck, and serum levels of bone turnover markers were examined. Loratadine at 0.5 and 5 mg/kg did not significantly affect the skeletal system of young rats. At 50 mg/kg, loratadine decreased the femoral length, increased content of calcium and phosphorus in the bone mineral of the vertebra, and tended to improve mechanical properties of the tibial metaphysis. High-dose loratadine slightly but significantly affected development of the skeletal system in rapidly growing rats.
Sections du résumé
BACKGROUND
BACKGROUND
Histamine H
PURPOSE
OBJECTIVE
The aim of the present study was to investigate the effects of loratadine on the skeletal system of young rats.
MATERIAL AND METHODS
METHODS
Loratadine (0.5, 5, and 50 mg/kg p.o. daily) was administered for 4 weeks to male Wistar rats, 6-week-old at the start of the experiment. Bone mass, mass of bone mineral, calcium, and phosphorus content in the bone mineral of the tibia, femur, and L-4 vertebra, histomorphometric parameters of the femur, mechanical properties of the proximal tibial metaphysis, femoral diaphysis and femoral neck, and serum levels of bone turnover markers were examined.
RESULTS
RESULTS
Loratadine at 0.5 and 5 mg/kg did not significantly affect the skeletal system of young rats. At 50 mg/kg, loratadine decreased the femoral length, increased content of calcium and phosphorus in the bone mineral of the vertebra, and tended to improve mechanical properties of the tibial metaphysis.
CONCLUSION
CONCLUSIONS
High-dose loratadine slightly but significantly affected development of the skeletal system in rapidly growing rats.
Identifiants
pubmed: 31576110
doi: 10.2147/DDDT.S215337
pii: 215337
pmc: PMC6767469
doi:
Substances chimiques
Histamine H1 Antagonists
0
Loratadine
7AJO3BO7QN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3357-3367Informations de copyright
© 2019 Folwarczna et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Endocrinol Metab Clin North Am. 2016 Jun;45(2):433-41
pubmed: 27241973
Am J Pathol. 2009 Apr;174(4):1426-34
pubmed: 19264900
Bone. 1993 Jul-Aug;14(4):595-608
pubmed: 8274302
Bone. 2017 Dec;105:219-225
pubmed: 28919366
Calcif Tissue Int. 2006 Aug;79(2):76-83
pubmed: 16927047
Int J Prev Med. 2013 Jun;4(6):624-30
pubmed: 23930179
Pol J Pharmacol. 2003 May-Jun;55(3):433-41
pubmed: 14506323
Calcif Tissue Int. 1999 Oct;65(4):272-5
pubmed: 10485976
Allergy Asthma Proc. 2009 Sep-Oct;30(5):482-6
pubmed: 19843401
J Bone Miner Res. 2006 Jan;21(1):89-96
pubmed: 16355277
J Toxicol Sci. 2007 Dec;32(5):555-64
pubmed: 18198485
Biochem Biophys Res Commun. 2002 Oct 25;298(2):240-6
pubmed: 12387822
J Cell Physiol. 1997 Oct;173(1):10-8
pubmed: 9326444
J Bone Miner Res. 2013 Jan;28(1):2-17
pubmed: 23197339
Pharmacology. 2010;85(5):311-8
pubmed: 20453555
Exp Physiol. 2006 May;91(3):561-70
pubmed: 16513821
PLoS One. 2013 Dec 04;8(12):e81569
pubmed: 24324705
Reprod Toxicol. 2013 Jul;38:16-24
pubmed: 23434729
J Intern Med. 1993 Aug;234(2):143-8
pubmed: 8340736
Arch Dis Child Educ Pract Ed. 2015 Jun;100(3):122-31
pubmed: 25147323
Mech Ageing Dev. 1987 May;38(3):287-93
pubmed: 2887716
Am J Med. 2008 Dec;121(12):1085-91
pubmed: 19028205
Bone. 2011 Apr 1;48(4):768-76
pubmed: 21185417
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Mol Nutr Food Res. 2013 Oct;57(10):1772-84
pubmed: 23754597
J Bone Miner Res. 2015 May;30(5):786-95
pubmed: 25418329
Bone. 2002 Jan;30(1):131-6
pubmed: 11792575
Bone. 2004 Jan;34(1):91-9
pubmed: 14751566
Gastroenterology. 2010 Jul;139(1):93-101
pubmed: 20353792
Endocrinology. 2015 Feb;156(2):548-54
pubmed: 25456072
J Clin Invest. 2005 Dec;115(12):3318-25
pubmed: 16322775
J Pediatr Orthop. 2016 Jun;36(4):e45-8
pubmed: 26177059
Pharmacol Rep. 2014 Feb;66(1):93-9
pubmed: 24905313
Xenobiotica. 2005 Feb;35(2):155-89
pubmed: 16019945
J Cell Biochem. 2016 Sep;117(9):2089-96
pubmed: 26869358
Bone. 2006 Jan;38(1):59-66
pubmed: 16249129
World Allergy Organ J. 2008 Sep;1(9):145-55
pubmed: 23282578
Bone. 2013 Nov;57(1):269-71
pubmed: 23973557
Lancet. 2006 Aug 26;368(9537):733-43
pubmed: 16935684
Ann Allergy Asthma Immunol. 2011 Feb;106(2 Suppl):S2-5
pubmed: 21277530
Ann Fam Med. 2011 May-Jun;9(3):257-67
pubmed: 21555754
Angew Chem Int Ed Engl. 2002 Sep 2;41(17):3130-46
pubmed: 12207375
Osteoporos Int. 2009 Dec;20(12):1989-98
pubmed: 19333676
J Biomech. 2009 Aug 25;42(12):1793-803
pubmed: 19540500
PLoS One. 2015 Jul 02;10(7):e0131869
pubmed: 26135565
Pharmacol Rep. 2011;63(4):1040-9
pubmed: 22001992
Osteoporos Int. 2016 Aug;27(8):2411-21
pubmed: 26892042
Injury. 2007 Aug;38(8):913-22
pubmed: 17628559
Osteoporos Int. 2006;17(3):484-91
pubmed: 16432646
Front Pharmacol. 2017 Oct 04;8:693
pubmed: 29046637
Am J Orthod Dentofacial Orthop. 2011 Apr;139(4):e323-9
pubmed: 21457838